Key differences: use, duration, and route The first practical difference is the intended length of treatment
Annual physicals, lab work, chronic condition management, and a care team that actually knows your name all in Summerlin
What is the half-life of IGF-1 LR3 compared to native IGF-1
Overview of GLP-1 Receptor Agonists The major GLP-1 receptor agonists available on the market currently are: Dulaglutide (Trulicity) Exenatide extended release (Bydureon BCise) Exenatide (Byetta) Semaglutide (Ozempic, Rybelsus) Liraglutide (Victoza, Saxenda) Lixisenatide (Adlyxin) What is Dulaglutide (Trulicity) and its mechanism of action Dulaglutide, sold as Trulicity, is an injectable GLP-1 receptor agonist medication designed for the treatment of type 2 diabetes
In fact, 68% of patients who started Wegovy, a GLP-1 medication approved for weight loss, stopped taking it within one year due to side effects
The FDA ended shortage-related compounding in 2025 and, on April 30, 2026, proposed keeping tirzepatide off the 503B bulks list permanently